Canada Markets closed

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1450+0.0050 (+3.57%)
At close: 3:27PM EST
Sign in to post a message.
  • b
    brwolf
    When the top dog shows this much faith it is always a good sign. GLTA

    Doug Janzen, of 2820 - 200 Granville St., Vancouver, BC, V6C 1S4, today announced that on Friday, January 15, 2021, he acquired ownership of 200,000 common shares ("Common Shares") in the capital of Aequus Pharmaceuticals Inc. ("Aequus"), a company with a head office at 2820 - 200 Granville St., Vancouver, BC, V6C 2R3 at an average purchase price of $0.12175 per Common Share for an aggregate purchase price of $24,350. Mr. Janzen acquired ownership of the Common Shares through the facilities of the TSX Venture Exchange.
  • M
    MFO
    20% up and nice volume 👍
  • Y
    Yves
    We're going from weak hands to strong hands...
  • M
    MFO
    When higher than 0,155 , it will be a very positive sign …… soon 😊
  • j
    jbb
    On TDAMERITRADE there appears to have 221500 shares at .1021 on the ask???
  • M
    MFO
    Record Third Quarter Revenues – 67% Increase Over Same Period Last Year

    Even if the 3rd Evolve product will be sold OTC (or not), the future is bright as there will be new developments and products for this company .
  • b
    brwolf
    All looks relatively promising and plenty in the pipeline. I agree with not moving forward on the 3rd product if OTC is the end result. GLTA
  • f
    frankii
    Wow, I see few of you still here. I have sold everything at nickel for 46k lost on this #$%$ but I made over 100k from Trvn so not to bad for the trade. Maybe this stock will shine one day and wish everyone luck.
  • D
    Doug
    I may not seem to understand the ophthalmology/OD market in Canada, but you demonstrate a complete lack of market intelligence. There are 3 innovative companies driving the preservative free dry eye market. Labtician Thea with 3 unique PF products sold only in clinics, i-med pharma has another 3 products sold only in clinics and then there is candor vision. They were the first to bring pf multiuse dry eye products. They are sold in pharmacy and clinics. Then there is Hydrasense a pf multiuseproduct sold in pharmacies on the shelf. All segments are covered mild moderate severe, gels, liquids, preservative free multdose. In total 15 brands. like I said good luck!
  • T
    Tim
    Rooty, time to take the pills again, breathe in, breathe out, it is really not healthy to push your bloodpressure on every single detail. It is also completely useless. Nothing changes, no matter if anyone decides to sell some shares or not. We will see good news soon.
  • D
    Doug
    A product launch during covid will be a challenge. individual practices are locked in with suppliers. The current suppliers have developed a process for reordering product. Medicom drops have no real points of differentiation vs other dry eye products. why switch? $$, what your margins. Samples?
    Finally pharmacies are not going to take on another line, without removing one. Plus if you want pharmacy shelving, bring the end asile display, advertising in the SDM Flyer. Don't forget you need to reimburse for expired product. Good Luck
  • a
    andre
    I would like to summarize and furthermore add some more information to the news of last week.

    This is by now the news with the biggest impact on the business of AQS.

    British Columbia decided to replace the existing product with Sandoz Tacrolismus. We talk about approx. 5.000 patients and additional 300 to 400 new patients every year, needing Sandoz Tacrolismus on a daily basis. We talk about a business worth up to 20 Mio CADs for the current product.

    And the best is: The impact on the revenue startet already end of last year and will rapidly grow this quarter, as all patients should have Sandoz Tacrolismus end of March latest.

    AQS will not generate 20 Mio CADs per year, as:

    - they will not get the whole revenue, Sandoz will have of course a part of it.
    - Sandoz is cheaper than the current product
    - Tacro IR patients will not (yet) be provided with Sandoz Tacro

    Anyway: Due to this deal, AQS will generate several millions CAD revenue year over year, without having additional sales cost.

    Therefore, we could be near to break even in a few quarters.

    And we have to see, if there is a need at all to raise new money, as revenue will grow rapidly from January on.

    This is the current situation without! the Evolve opportunity in Canada and later in in the US.

    It will be interesting to see, when the market starts to understand the complete new situation of AQS.
  • b
    brwolf
    We went down on a little over $50K worth of moves on both exchanges combined. Miniscule movement and insignificant in my eyes. The other two products will most likely be approved in the coming days/weeks. Sales will follow soon after as management has stated the legwork is already in place. I will say it again...we should see a slight bump in sales for the 4th Qtr but I think the tell will be 2021 1st Qtr sales volume as to the significance of the new product launch. I'm not sure why the slight selloff would worry anyone at this point as that is nothing new here on good news.
  • M
    MFO
    Waiting for this approval … products are fine and now the management team seems ready for growth
  • J
    JPV
    New record revenue of 579.5k CAD in Q1/2020 with a strong +76% compared to Q1/2019. Operational breakeven anticipated for Q4/2020, profitability for 2021.
    New record revenue of 579.5k CAD in Q1/2020 with a strong +76% compared to Q1/2019. Operational breakeven anticipated for Q4/2020, profitability for 2021.
    seekingalpha.com
  • Y
    Yves
    I think there is a good probability that the company has reached profitability by now and is already in good shape...
    How else could we explain they could operate till now without more financing...
    They have certainly increased their sale of Tacrolimus for the reasons that everybody knows...
    On top of that, they reduced expenses...
    We just have to wait for another 6 months to see more improvements but nobody will go out of business in the meantime...
  • A
    A
    For the last 2 or so years, there has been an incongruence between the optimism on this message board and the share price. I still passively follow this company, although I am presently not invested in it. I wonder if now is a good time to buy cheap shares, or if this one is a trap. Perhaps short term trades when the shares dip below 17 cents (Canadian) are the way to play this one. What do the optimists have to say about things now that the price per share is lower than where it was over one year ago?
  • D
    Daniel
    Tacrolimus agaist Covid-19 / Coronavirus!

    https://www.sciencedaily.com/releases/2020/03/200330152143.h… A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19. The study, led by researchers at King's College London, also found other types of drugs, such as TNF blockers and JAK inhibitors safe to use. 89 existing studies on other coronavirus strains such as MERS and SARS, as well as the limited literature on COVID-19, were analysed to find out if certain pain medications, steroids, and other drugs used in people already suffering from diseases should be avoided if they catch COVID-19. Some patients, for example those with cancer, are already given immunosuppressive drugs -- therapies that can lower the body's immune system -- or immunostimulant drugs -- therapies that boost it. If these patients then catch COVID-19, doctors need to know what medication to stop. Dr Mieke Van Hemelrijck, a cancer epidemiologist and an author on the paper, said "This pandemic has led to challenging decision-making about the treatment of COVID-19 patients who were already critically unwell. In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune suppressive medication." The article has been published in ecancermedicalscience, an open access oncology journal, and is authored by researchers from King's College London and Guy's and St. Thomas NHS Foundation Trust, London. There had been some speculation that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen might make things worse for some COVID-19 patients, but the researchers did not find evidence to support this statement. Other types of drugs such as TNF blockers and JAK inhibitors, used to treat arthritis or other forms of inflammation, were also found to be safe to use. Another class of drug known as anti-interleukin-6 agents is being investigated for helping to fight COVID-19, although there is no conclusive proof yet. The researchers found that low amounts of prednisolone or tacrolimus therapy may be helpful in treating COVID-19. Co- author, Dr Sophie Papa, a medical oncologist and immunologist said: "Current evidence suggests that low dose prednisolone (a steroid used to treat allergies) and tacrolimus therapy (an immunosuppressive drug given to patients who have had an organ transplant) may have beneficial impact on the course of coronavirus infections. However further investigation is needed." As more people catch the disease, researchers will continue to investigate how it interacts with commonly used medications and make further guidance recommendations.
  • Y
    Yves
    file:///C:/Users/Yves/Downloads/Quarterly-Summary-of-Investment-Portfolio%20(1).pdf

    Interesting!